United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 0.8mmol/ml) solution for infusion 20ml ampoules (synchrony pharma ltd - magnesium sulfate heptahydrate - solution for infusion - 200mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

aurum pharmaceutical limited - magnesium sulphate heptahydrate - solution for injection and concentrate for infusion - 50 percent weight/volume - electrolyte solutions; magnesium sulfate

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - magnesium sulphate heptahydrate - solution for injection/infusion - 50 percent weight/volume - electrolyte solutions; magnesium sulfate

Israel - English - Ministry of Health

inovamed ltd - magnesium sulfate as heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate 50%w/v inovamed is indicated for:1. the treatment of magnesium deficiency in hypomagnesaemia. 2. the prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutrition. 3. the control and prevention of seizures in severe pre-eclampsia. 4. the control and prevention of recurrent seizures in eclampsia

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

x-gen pharmaceuticals, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - magnesium sulfate heptahydrate 50%{relative};   - solution for injection - 50% w/v - active: magnesium sulfate heptahydrate 50%{relative}   excipient: hydrochloric acid sodium hydroxide water for injection - mineral supplement indicated in the treatment of magnesium deficiency in hypomagnesaemia and to prevent further seizures associated with eclampsia.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.